Rhode Island Medicaid and GLP-1s

What changed, and what the document says

1. The date, and the reason

   Not covered

   This isn't a clinical review. It's a budget instruction, and the memo leads with that.

   “Pursuant to the Rhode Island State Fiscal Year 2027 Enacted Budget, beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss.”

   Rhode Island Executive Office of Health and Human Services — August 5, 2026

2. Which four

   Not covered

   Named individually, which is rarer than it should be. Foundayo on the list makes this one of the first cuts to reach an oral GLP-1.

   “Foundayo (Orforglipron)”

   Rhode Island Executive Office of Health and Human Services — August 5, 2026

3. The word doing the work

   Conditions apply

   Solely. A different indication is a different question, and the memo keeps that door open.

   “The medications that Rhode Island Medicaid will no longer cover when used solely for weight loss include:”

   Rhode Island Executive Office of Health and Human Services — August 5, 2026

4. Keeping one of them

   Conditions apply

   An existing approval doesn't carry over. It's a fresh request with clinical records attached.

   “If continued treatment with one of these medications listed above is medically necessary for an indication other than weight loss, providers must submit a new PA request with the appropriate clinical documentation.”

   Rhode Island Executive Office of Health and Human Services — August 5, 2026

5. Under 21 is a separate track

   Covered

   The federal child-health benefit still applies, and the memo says every one of those requests gets reviewed under it.

   “For members younger than 21 years of age, all PA requests must be reviewed for medical necessity in accordance with Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) requirements.”

   Rhode Island Executive Office of Health and Human Services — August 5, 2026

6. What's being taken away

   Context

   The current list still runs a full obesity-drug class, with every product in it behind a human reviewer rather than a claims edit.

   “Clinical Prior Authorization Required for Entire Class/Manual PA”

   Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026

7. The class is three years old

   Context

   Rhode Island stood this up in October 2023 and reviewed it in May 2026, four months before deciding to end it.

   “Status Implementation: 10/03/2023”

   Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026

8. The diabetes rule, unchanged

   Covered

   Nothing in the memo touches this one. A GLP-1 for diabetes still starts with a metformin history.

   “Clinical Criteria for GLP-1 Receptor Agonists - History of either metformin or TZD therapy in the past 90 days”

   Rhode Island Executive Office of Health and Human Services — Updated: 6/16/2026

Which of these companies serve Rhode Island?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

17 of those lists name Rhode Island: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, TeleClinic, Tyde Wellness, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, and Hormonally Balanced. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.